The estimated Net Worth of David Kai Yuen Poon is at least $9.68 Tausend dollars as of 6 May 2019. Dr Poon owns over 800 units of Zymeworks BC Inc stock worth over $9,680 and over the last 6 years he sold ZYME stock worth over $0.
Dr has made over 1 trades of the Zymeworks BC Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 800 units of ZYME stock worth $2,824 on 6 May 2019.
The largest trade he's ever made was exercising 800 units of Zymeworks BC Inc stock on 6 May 2019 worth over $2,824. On average, Dr trades about 400 units every 0 days since 2019. As of 6 May 2019 he still owns at least 800 units of Zymeworks BC Inc stock.
You can see the complete history of Dr Poon stock trades at the bottom of the page.
Dr. David Poon Ph.D. is the VP of Bus. Devel. and Alliance Management at Zymeworks BC Inc.
David's mailing address filed with the SEC is C/O ZYMEWORKS INC., 1385 WEST 8TH AVENUE, SUITE 540, VANCOUVER, A1, V6H 3V9.
Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1 und Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Zymeworks BC Inc executives and other stock owners filed with the SEC include: